These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Physicians are concerned about generic drug bioequivalence, but often unaware of FDA standards. Am J Health Syst Pharm; 1997 Dec; 54(24):2799-800. PubMed ID: 9428948 [No Abstract] [Full Text] [Related]
3. Bioequivalence of thyroid preparations: the final word? Gibaldi M AAPS J; 2005; 7(1):E59-60. PubMed ID: 16493834 [No Abstract] [Full Text] [Related]
4. Bioequivalence/bioavailability retention samples. Ransom C Qual Assur; 1993; 2(1-2):42-3. PubMed ID: 8156218 [No Abstract] [Full Text] [Related]
5. Clinical Endpoint Bioequivalence Studies Are Needed: A Perspective From Brand Drugs. Krishna R; Kesisoglou F Clin Pharmacol Ther; 2019 Feb; 105(2):298-300. PubMed ID: 30456848 [No Abstract] [Full Text] [Related]
6. Some thoughts on drug interchangeability. Chow SC; Song F; Chen M J Biopharm Stat; 2016; 26(1):178-86. PubMed ID: 26366703 [TBL] [Abstract][Full Text] [Related]
7. Current regulatory approaches of bioequivalence testing. Karalis V; Macheras P Expert Opin Drug Metab Toxicol; 2012 Aug; 8(8):929-42. PubMed ID: 22681436 [TBL] [Abstract][Full Text] [Related]
8. United States Food and Drug Administration requirements for approval of generic drug products. Meyer MC J Clin Psychiatry; 2001; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846 [TBL] [Abstract][Full Text] [Related]
9. Bioequivalence Evaluations of Generic Dry Powder Inhaler Drug Products: Similarities and Differences Between Japan, USA, and the European Union. Kuribayashi R; Yamaguchi T; Sako H; Takishita T; Takagi K Clin Pharmacokinet; 2017 Mar; 56(3):225-233. PubMed ID: 27461251 [TBL] [Abstract][Full Text] [Related]
10. The generic drug approval process. Rheinstein PH Am Fam Physician; 1993 Dec; 48(8):1357-60. PubMed ID: 8249762 [No Abstract] [Full Text] [Related]
11. Risk-Based Bioequivalence Recommendations for Antiepileptic Drugs. Li Z; Fang L; Jiang W; Kim MJ; Zhao L Curr Neurol Neurosci Rep; 2017 Sep; 17(11):82. PubMed ID: 28929357 [TBL] [Abstract][Full Text] [Related]
12. Generic substitution: issues for problematic drugs. Henderson JD; Esham RH South Med J; 2001 Jan; 94(1):16-21. PubMed ID: 11213935 [TBL] [Abstract][Full Text] [Related]
13. Assessing bioequivalence and drug interchangeability. Chen M; Chow SC J Biopharm Stat; 2017; 27(2):272-281. PubMed ID: 27936343 [TBL] [Abstract][Full Text] [Related]
14. Initial responses to recommendations of the Blue Ribbon Committee on Generic Medicines. Heller WM Am J Hosp Pharm; 1993 Feb; 50(2):318-22. PubMed ID: 8480792 [No Abstract] [Full Text] [Related]
15. On safety margin for drug interchangeability. Zheng J; Chow SC; Song F J Biopharm Stat; 2017; 27(2):293-307. PubMed ID: 27911675 [TBL] [Abstract][Full Text] [Related]
16. Generics Substitution, Bioequivalence Standards, and International Oversight: Complex Issues Facing the FDA. Bate R; Mathur A; Lever HM; Thakur D; Graedon J; Cooperman T; Mason P; Fox ER Trends Pharmacol Sci; 2016 Mar; 37(3):184-191. PubMed ID: 26687297 [TBL] [Abstract][Full Text] [Related]
17. Generic drugs. Save money--but is there a cost? Roberts SS Diabetes Forecast; 2002 Nov; 55(11):51-3. PubMed ID: 14768605 [No Abstract] [Full Text] [Related]
18. Generic and alternative brand-name pharmaceutical equivalents: select with caution. Hendeles L; Hochhaus G; Kazerounian S Am J Hosp Pharm; 1993 Feb; 50(2):323-9. PubMed ID: 8480793 [No Abstract] [Full Text] [Related]
20. Trying times for generic medicines in the USA. Lancet; 2013 Mar; 381(9872):1072. PubMed ID: 23540840 [No Abstract] [Full Text] [Related] [Next] [New Search]